A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4

American Journal of Nephrology

Volumn 26, Issue 1, 2006, Pages 105-114

  Abboud, Hanna ^a   Coyne, Daniel ^b   Smolenski, Olgierd ^c   Anger, Michael ^d   Lunde, Norman ^e   Qiu, Ping ^f   Hippensteel, Rich ^f   Pradhan, Rajendra S ^f   Palaparthy, Rameshraja V ^f   Kavanaugh, Anne ^f   Melnick, Joel Z ^f   Williams, Laura A ^f   Batlle, Daniel ^g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c Provincial Hospital   (Poland)

^d UNIVERSITY OF COLORADO   (United States)

^e Twin Cities Clinical Research   (United States)

^f ABBOTT LABORATORIES   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Hypercalcemia; Hyperphosphatemia; Intermittent dosing, paricalcitol; Once daily dosing, paricalcitol; Pulse dosing, paricalcitol; Vitamin D; Vitamin D receptor activator

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; PLACEBO;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CAPSULE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; STEADY STATE; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM; CAPSULES; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PROSPECTIVE STUDIES; VITAMINS;

EID: 33645699069     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092033     Document Type: Article

References (24)

1. Gonzalez EA, Sachdeva A, Oliver DA, et al: Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004;24:503-510.
2. De Boer IH, Gorodetskaya I, Young B, et al: The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002;13:2762-2769.
3. Panichi V, Andreini B, De Pietro S, et al: Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure. Clin Nephrol 1998;49:245-250.
4. 3 in early renal failure. Annu Rev Med 1992;43:227-237.
5. Llach F, Velasquez Forero F: Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001;38(5 Suppl 5):S20-S33.
6. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999;73:14-19.
7. Felsenfeld AJ, Rodriguez M: Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol 1999;10:878-890.
8. Ho LT, Sprague SM: Renal osteodystrophy in chronic renal failure. Semin Nephrol 2002;22:488-493.
9. 3, and radiology in end-stage renal disease. Kidney Int 1993;44:1071-1077.
10. Sanchez CP, Goodman WG, Salusky IB: Prevention of renal osteodystrophy in predialysis patients. Am J Med Sci 1999;317:398-404.
11. Nordal KP, Dahl E, Halse J, et al: Long-term low-dose calcitriol treatment in predialysis chronic renal failure: can it prevent hyperparathyroid bone disease? Nephrol Dial Transplant 1995;10:203-206.
12. Hamdy NA, Kanis JA, Beneton MN, et al: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995;310:358-363.
13. 3 in experimental renal hyperparathyroidism. Kidney Int 1993;44:1259-1265.
14. Klaus G, Mehls O, Hinderer J, et al: Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? Lancet 1991;337:800-801.
15. Coburn JW: Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int Suppl 1990;29:54-61.
16. 3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism. Nephron 1991;57:23-28.
17. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998;9:1427-1432.
18. Sprague SM, Llach F, Amdahl M, et al: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-1490.
19. Coyne D, Acharya M, Qiu P, et al: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006;47:263-276.
20. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
21. 3. Nephron 1991;58:288-294.
22. 3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002;139:279-284.
23. Staniforth ME, Cheng SC, Coyne DW: Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Clin Nephrol 2005;63:454-460.
24. Coburn JW, Maung HM, Elangovan L, et al: Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004;43:877-890.